BPC-157 + Selank: The Gut-Brain Axis Stack
BPC-157
Gastric pentadecapeptide for gut mucosal repair and neuroprotection
Selank
Anxiolytic peptide modulating GABA and serotonin systems
The gut-brain axis is a bidirectional communication network between the gastrointestinal tract and the central nervous system. Disruption of this axis is implicated in conditions ranging from IBS to anxiety and depression. This stack targets both ends of the axis: BPC-157 for gut healing and neuroprotection, and Selank for anxiolytic and mood-stabilising effects.
BPC-157, derived from human gastric juice, has extensive preclinical data showing gut mucosal protection and repair, plus emerging evidence for neuroprotective effects via the gut-brain axis. Selank, approved in Russia as an anxiolytic, modulates GABA and serotonin systems to reduce anxiety without sedation.
**Critical Disclaimer:** Neither peptide is approved for this combination use. Selank is approved in Russia only. BPC-157 is a research compound. This content is educational only.
Synergistic Mechanism
Gut-Brain Axis Synergy
The Gut-Brain Connection
The gut and brain communicate bidirectionally through:
- The vagus nerve (direct neural connection)
- Gut microbiome metabolites (serotonin, GABA, short-chain fatty acids)
- Immune signalling (cytokines from gut-associated lymphoid tissue)
- The enteric nervous system ("second brain" — 500 million neurons in the gut)
90% of the body's serotonin is produced in the gut. Gut inflammation directly affects brain chemistry and mood.
BPC-157: Gut End
- Heals gut mucosal damage (ulcers, IBD-like lesions in animal models)
- Reduces intestinal inflammation (TNF-α, IL-6 downregulation)
- Promotes angiogenesis in damaged gut tissue
- Modulates dopaminergic and serotonergic systems (neuroprotective)
- Stable in gastric acid — uniquely suited for oral gut-targeting administration
Selank: Brain End
- Enhances GABA-A receptor sensitivity (calming without sedation)
- Modulates serotonin metabolism (mood stabilisation)
- Upregulates BDNF (neuroplasticity and stress resilience)
- Reduces neuroinflammation (IL-6 modulation)
- No dependence, tolerance, or withdrawal
The Combined Logic
1. BPC-157 repairs gut barrier integrity → reduces gut-derived inflammatory signals to brain
2. Selank calms central anxiety → reduces stress-mediated gut dysfunction
3. Both modulate serotonin systems from different ends of the axis
4. Net effect: breaking the gut-brain dysfunction cycle from both directions
Research Evidence
Research Evidence
BPC-157 and Gut Health
- Extensive animal data showing protection against NSAID-induced ulcers, alcohol damage, and IBD-like lesions
- Demonstrated gut barrier protection and accelerated mucosal healing
- Neuroprotective effects observed in multiple brain injury models
- Limited Phase I/II data for inflammatory bowel disease
Selank and Anxiety
- Approved anxiolytic in Russia (clinical safety and efficacy data)
- Zozulya et al. (2008): Comparable to benzodiazepines without side effects
- Gene expression studies confirm GABA/serotonin modulation
- BDNF upregulation validated in preclinical studies
Gut-Brain Axis Research
- Growing body of literature supporting bidirectional gut-brain communication
- Probiotics and gut-healing interventions shown to improve mood scores
- Stress-reduction interventions shown to improve GI symptoms
- No studies on this specific peptide combination
Theoretical Protocol
Theoretical Protocol
BPC-157:
- Dose: 200-500 mcg
- Route: Oral (stable in gastric acid for direct gut targeting) or subcutaneous
- Frequency: Twice daily (morning and evening)
- Oral administration is uniquely relevant for this stack (direct gut contact)
Selank:
- Dose: 250-500 mcg intranasal (1-3 sprays per nostril)
- Frequency: 2-3 times daily
- Duration: 4-8 weeks (no tolerance development)
**Cycle:** 6-12 weeks, with reassessment
⚠️ Theoretical extrapolations only. No approved combination protocols exist.
Timing & Scheduling
Timing Considerations
- BPC-157 (oral): Can be taken with or without food due to gastric acid stability
- BPC-157 (injectable): Flexible timing
- Selank: Morning and afternoon doses for daytime anxiolysis; evening dose for sleep support
- No known interactions between BPC-157 and Selank
- Different administration routes (oral/SC vs intranasal) simplify co-administration
Expected Outcomes
Expected Research Outcomes
**BPC-157:** Reduced gut inflammation, improved mucosal integrity, potential reduction in GI symptoms
**Selank:** Reduced anxiety, improved stress resilience, better sleep quality, enhanced cognitive clarity
**Combined:** Theoretical breaking of the gut-brain dysfunction cycle — gut healing reducing inflammatory brain signals while anxiety reduction decreases stress-mediated gut dysfunction
Timeline:
- Week 1: Selank anxiolytic effects typically noticeable within days
- Weeks 2-4: BPC-157 gut healing effects may begin
- Weeks 4-8: Full protocol effect; assess both GI and mood endpoints
Safety Considerations
Safety Considerations
- BPC-157: Limited human safety data; well-tolerated in preclinical studies and anecdotal reports. Theoretical angiogenesis concern in cancer patients
- Selank: Well-characterised safety from Russian clinical use; no dependence, tolerance, or withdrawal. Mild nasal irritation possible
- Combined: No known interactions. Different administration routes reduce interaction risk
- Both peptides affect serotonin systems — theoretical concern about serotonergic excess, though mechanisms are modulatory rather than direct agonism
- Monitor: Mood, GI symptoms, sleep quality, any unusual symptoms
Frequently Asked Questions
Conclusion
The BPC-157 + Selank stack targets the gut-brain axis from both ends — gut healing and anxiety reduction. For individuals where stress and gut dysfunction are interconnected (a common clinical pattern), this dual approach is mechanistically logical. Both peptides have reasonable individual evidence and complementary safety profiles.